DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Leydig cell hypoplasia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLeydig cell hypoplasia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for leydig cell hypoplasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
luteinizing hormone/choriogonadotropin receptor (LHCGR) — LHCGR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2-morpholin-4-ylethanoylaminodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7FIH · 3.2 Å · ligand 5-azanyl-N-tert-butyl-2-methylsulfanyl-4-[3-(2-morpholin-4-ylethanoylamino)phenyl]thieno[2,3-d]pyrimidine-6-carboxamide (55Z). Experimental structure, not a prediction.
What the evidence adds up to
Twenty-two patients with Leydig cell tumour were treated with conservative surgery between 1987 and 2006 in a multicentre European study. Mean follow-up was 47 months, and no local recurrence or metastasis was observed. Mean nodule size was 1.11 cm. Preoperative FSH and LH were high in four patients. Six patients (27.3%) underwent abdominal CT during follow-up. The authors concluded that in select cases with motivated patients, conservative surgery was feasible and safe.
Two review papers discuss the regulation of Leydig cell function. One from 1986 covers pituitary, testicular and intracellular regulatory mechanisms, with emphasis on local paracrine and autocrine interactions. A 2022 mini-review summarises transcription factors important for fetal and adult Leydig cell differentiation and function, including some previously unknown to this cell type.
No abstract addresses Leydig cell hypoplasia directly. The surgical study concerns benign Leydig cell tumour, not hypoplasia. The reviews describe normal Leydig cell regulation and gene expression but do not report any therapeutic intervention or outcome for hypoplasia.
What is missing is any clinical trial, any drug tested, any patient with Leydig cell hypoplasia treated and followed. No abstract provides survival, response rates, or sample sizes for hypoplasia. The gap is a complete absence of treatment data for this specific condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Urology · 2007 · 75 citations
Conservative Surgical Therapy for Leydig Cell Tumor
AbstractPURPOSE: We performed a long-term evaluation of conservative surgical treatment of benign Leydig cell tumor. MATERIALS AND METHODS: A multicenter retrospective clinical study was performed at 6 European centers. Case files of all patients diagnosed with Leydig cell tumor and treated with conservative surgery were examined. Patients underwent physical examination, hormone and tumor marker assays, scrotal and abdominal ultrasound, chest x-ray, and an endocrinological examination. RESULTS: From 1987 to 2006, 22 patients with Leydig cell tumor underwent conservative surgery. Mean patient age was 35 years (range 5 to 61). Mean followup was 47 months (range 1 to 230). No local recurrence or metastasis was observed. Patients presented with a palpable testicular nodule (3 patients, 13.7%) or a nodule diagnosed by ultrasound (15 patients, 68.2%), gynecomastia (2 patients, 9.1%), precocious pseudopuberty (1 patient, 4.5%) or scrotal pain (1 patient, 4.5%). Three patients were monorchid after contralateral orchiectomy for inguinal hernia repair (1 patient, 28 years before surgery) and nonseminomatous germ cell tumor (2 patients, 1 month and 6 years before surgery). Diagnosis after frozen section examination was Leydig cell tumor in 20 of 22 cases (91.0%). Mean histological size of the nodule was 1.11 cm (range 0.5 to 2.5). Preoperative FSH and LH levels were high in 4 patients. Tumor markers were normal before and after surgery. Followup was conducted for all patients every 3 to 6 months with physical examination, tumor markers, scrotal and abdominal ultrasound, chest x-ray. Six patients (27.3%) underwent abdominal computerized tomography. CONCLUSIONS: When diagnosed early Leydig cell tumors present a favorable followup. In select cases with motivated patients, conservative surgery proved to be a feasible and safe choice.
Current aspects of Leydig cell function and its regulation
AbstractRecent findings on Leydig cell function and its regulation are discussed. Regulatory mechanisms at different organizational levels, i.e. at the level of the pituitary, the testis and the intracellular elements, are briefly reviewed as well as the transmission and the modulation of the hormonal signal at the Leydig cell membrane. Special emphasis is given to local paracrine and autocrine regulatory interactions operating at the level of the testis.
Frontiers in Endocrinology · 2022 · 46 citations · open access
Transcription Factors in the Regulation of Leydig Cell Gene Expression and Function
AbstractCell differentiation and acquisition of specialized functions are inherent steps in events that lead to normal tissue development and function. These processes require accurate temporal, tissue, and cell-specific activation or repression of gene transcription. This is achieved by complex interactions between transcription factors that form a unique combinatorial code in each specialized cell type and in response to different physiological signals. Transcription factors typically act by binding to short, nucleotide-specific DNA sequences located in the promoter region of target genes. In males, Leydig cells play a crucial role in sex differentiation, health, and reproductive function from embryonic life to adulthood. To better understand the molecular mechanisms regulating Leydig cell differentiation and function, several transcription factors important to Leydig cells have been identified, including some previously unknown to this specialized cell type. This mini review summarizes the current knowledge on transcription factors in fetal and adult Leydig cells, describing their roles and mechanisms of action.
Mutations in a novel primate-specific cryptic exon of the LHCGR gene cause Leydig cell hypoplasia
AbstractLeydig cell hypoplasia (LCH), an autosomal recessive 46,XY disorder of sex differentiation, is characterized by a predominantly female phenotype with blind ending vagina, absence of breast development, primary amenorrhea due to the presence of testicular structures. It is caused by mutations in the luteinizing hormone/chorionic gonadotropin receptor (LHCGR), which either impair LH/CG binding or signal transduction. However, molecular analysis revealed that the LHCGR is apparently normal in about 50% of patients with the full clinical phenotype of LCH.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
